We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Innovative Polymeric Absorbable Suture

By HospiMedica staff writers
Posted on 24 Apr 2007
An absorbable suture is the first medical device derived from a new class of biopolymers produced by recombinant DNA technology.

The absorbable suture is made from TephaFlex, a member of the new class of biopolymers, which have mechanical and biological properties that are uniquely applicable to implantable medical devices. More...
Compared to synthetic polymers such as polylactic acid (PLA) and polyglycolic acid (PGA), TephaFlex material is tougher and more flexible, with an absorption rate and degradation profile that are compatible with human tissue repair and replacement applications. However, unlike other biopolymers such as collagen and hyaluronate, TephaFlex is thermoplastic and can be fabricated into virtually any shape or form--including fibers, films, tubes, foams, textiles, microspheres, and molded constructs--using a wide range of conventional melt and solvent processing techniques.

The absorbable suture is one of the strongest absorbable fibers known, offering up to 50% greater tensile strength than monofilament absorbable sutures. In addition to high strength, the suture also offers surgeons improved flexibility, good knot security, and prolonged strength retention when implanted. The TephaFlex absorbable suture is a product of Tepha (Cambridge, MA, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"We are delighted that the FDA has cleared the TephaFLEX absorbable suture,” said Dr. Simon Williams, President and CEO of Tepha. "The company's novel biopolymer technology can now be further applied to the development of a range of medical devices to meet unmet clinical needs.”


Related Links:
Tepha

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.